Russell Investments Group Ltd. lifted its holdings in Humana Inc. (NYSE:HUM – Free Report) by 9.2% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 413,336 shares of the insurance provider’s stock after purchasing an additional 34,831 shares during the quarter. Russell Investments Group Ltd.’s holdings in Humana were worth $158,101,000 as of its most recent filing with the SEC.
Other large investors also recently modified their holdings of the company. Eurizon Capital SGR S.p.A. grew its position in Humana by 1.5% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 21,164 shares of the insurance provider’s stock valued at $8,078,000 after buying an additional 303 shares in the last quarter. Maryland State Retirement & Pension System increased its stake in Humana by 10.8% during the 3rd quarter. Maryland State Retirement & Pension System now owns 7,307 shares of the insurance provider’s stock valued at $2,788,000 after buying an additional 710 shares during the period. Ritholtz Wealth Management raised its position in shares of Humana by 25.0% during the 3rd quarter. Ritholtz Wealth Management now owns 3,452 shares of the insurance provider’s stock worth $1,317,000 after buying an additional 691 shares in the last quarter. Jacobi Capital Management LLC bought a new stake in shares of Humana during the 3rd quarter worth about $61,000. Finally, First Command Advisory Services Inc. raised its position in shares of Humana by 279.5% during the 3rd quarter. First Command Advisory Services Inc. now owns 573 shares of the insurance provider’s stock worth $219,000 after buying an additional 422 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other news, insider Joseph Ventura sold 5,495 shares of the firm’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $433.85, for a total transaction of $2,384,005.75. Following the completion of the sale, the insider directly owned 21,910 shares of the company’s stock, valued at $9,505,653.50. This trade represents a 20.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.20% of the company’s stock.
Humana Stock Up 0.1%
HUM stock opened at $450.38 on Monday. Humana Inc. has a 52-week low of $163.11 and a 52-week high of $456.50. The company’s 50 day simple moving average is $408.53 and its 200-day simple moving average is $316.91. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.65 and a quick ratio of 1.65. The firm has a market capitalization of $54.09 billion, a P/E ratio of 43.81, a P/E/G ratio of 2.14 and a beta of 0.65.
Humana (NYSE:HUM – Get Free Report) last issued its earnings results on Friday, November 6th. The insurance provider reported ($0.70) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.30. The business had revenue of $41.16 billion during the quarter, compared to analysts’ expectations of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. Humana’s revenue was up 26.1% compared to the same quarter last year. During the same quarter last year, the firm posted $3.24 earnings per share. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, equities research analysts anticipate that Humana Inc. will post 9.66 EPS for the current year.
Humana Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 29th. Investors of record on Thursday, December 24th will be issued a dividend of $0.8850 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. The ex-dividend date is Thursday, December 24th. Humana’s dividend payout ratio (DPR) is currently 34.44%.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on HUM shares. HSBC cut shares of Humana to a “hold” rating in a report on Thursday, July 30th. UBS Group boosted their target price on Humana from $405.00 to $495.00 and gave the stock a “neutral” rating in a report on Monday, October 12th. Raymond James Financial restated an “outperform” rating on shares of Humana in a research report on Friday, November 6th. Robert W. Baird raised Humana from a “neutral” rating to an “outperform” rating and increased their price target for the company from $390.00 to $596.00 in a research note on Friday, October 9th. Finally, Wells Fargo & Company increased their price target on Humana from $502.00 to $602.00 and gave the company an “overweight” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $482.96.
View Our Latest Analysis on HUM
About Humana
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Further Reading
- Five stocks we like better than Humana
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Free Report).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
